CSIMarket
 
Bone Biologics Corporation  (BBLG)
Other Ticker:  
 
 
Price: $2.3300 $-0.16 -6.606%
Day's High: $2.563 Week Perf: -8.98 %
Day's Low: $ 2.30 30 Day Perf: -37.03 %
Volume (M): 13 52 Wk High: $ 54.22
Volume (M$): $ 31 52 Wk Avg: $5.58
Open: $2.49 52 Wk Low: $1.12



 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Bone Biologics Corporation
Bone Biologics Corporation is a biotechnology company that specializes in the development of innovative products for bone regeneration and tissue engineering. The company focuses on the commercialization of its proprietary technology platform, called the Nell-1 protein, which has shown great potential in stimulating bone growth and healing.

Bone Biologics aims to address the significant unmet medical need for effective treatments for bone fractures, spinal fusion, and other bone-related conditions. Their goal is to improve patient outcomes and quality of life by providing novel and advanced therapies that accelerate the body's natural healing process.

The company's flagship product, called Nell-1 Osteoinductive Biological Implant, is designed to promote bone regeneration in spinal fusion procedures. It has demonstrated impressive results in preclinical and clinical studies, showing superior bone growth and quality compared to existing treatments.

Bone Biologics Corporation is committed to advancing the field of regenerative medicine and revolutionizing the way bone injuries and diseases are treated. They continue to invest in research and development to expand their product pipeline and address additional applications in bone healing and regeneration.


   Company Address: 2 Burlington Woods Drive Burlington 1803 MA
   Company Phone Number: 552-4452   Stock Exchange / Ticker: NASDAQ BBLG
   BBLG is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Business Update

Bone Biologics Makes Significant Progress with NB1 Clinical Program in Spinal Fusion

Published Fri, Mar 1 2024 1:00 PM UTC

Bone Biologics Corporation, a renowned developer of orthobiologic products for spine fusion markets, is making notable advancements in its NB1 product candidate for spinal fusion. The company has received approval from the Human Research Ethics Committee (HREC) for a multicenter, prospective, randomized pilot clinical trial. As a result, Bone Biologics has successfully engag...

Stock Transactions

Bone Biologics Corporation Leverages Capital Raise to Drive Revolutionary Orthobiologic Technologies for Spine Fusion Market

Published Mon, Nov 20 2023 5:38 PM UTC

Bone Biologics Corporation Closes Registered Direct Offering and Initiates Private Placement to Accelerate Growth
BURLINGTON, Mass. - Bone Biologics Corporation (NASDAQ: BBLG), a leading developer of orthobiologic products for spine fusion markets, has successfully closed its registered direct offering under Nasdaq rules. The offering included 1,139,063 shares of common ...

Stock Issue News

Bone Biologics Corporation Announces Registered Direct Offering and Private Placement, Securing Additional Funding for Orthobiologic Products Development

Published Thu, Nov 16 2023 9:43 PM UTC


In a significant move towards advancing its orthobiologic products for the spine fusion markets, Bone Biologics Corporation (NASDAQ: BBLG) recently announced the execution of a definitive agreement for the issuance and sale of 1,139,063 shares of its common stock at a purchase price of $0.64 per share. Simultaneously, the company has also agreed to sell unregistered sha...

Bone Biologics Corporation

Bone Biologics Corporation Faces Significant Losses as Q1 2023 Return on Equity Plunges to -129.52%

The Biotech industry is known for its high-risk, high-reward environment with clinical trials taking years, sometimes even a decade, to complete. With such a lengthy research and development period, companies like Bone Biologics Corporation often see limited revenue streams for many years, instead relying on investment capital. This often results in the accumulation of net losses over time, and a negative return on equity (ROE), which dipped to -129.52 percent at the end of the Q1 2023.
In comparison to other companies in the Medical Equipment & Supplies industry, 99 other companies had higher ROEs, with Bone Biologics Corporation ranking 3129, down from zero in the previous quarter. While a negative ROE indicates low profitability, it can also highlight a company's need to invest in R&D, which can lead to exciting innovations and break-through therapies down the line.






 

Bone Biologics's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Bone Biologics does not provide revenue guidance.

Earnings Outlook
Bone Biologics Corporation does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com